65615-23-8

Upstream product

• 65615-22-7 7-(benzyloxy)-8-hydroxy-1H-isochromen-3(4H)-one 
• 77-78-1 dimethyl sulfate 
• 34918-57-5 methyl 3-bromo-4-hydroxyphenylacetate 
• 101111-25-5 methyl 2-(4-(benzyloxy)-3-bromophenyl)acetate 
• 28988-68-3 2-(4-(benzyloxy)-3-hydroxyphenyl)acetic acid 
• 74-88-4 methyl iodide 
• 5884-48-0 2-(4-(benzyloxy)-3-bromophenyl)acetic acid 

Downstream Products

• 65615-24-9 N-(4-(benzyloxy)-3-methoxyphenethyl)-2-(4-(benzyloxy)-2-(hydroxymethyl)-3-methoxyphenyl)acetamide 
• 924709-09-1 C₁₇H₁₅NO₆ 
• 30413-84-4 (-)-corydalmine 
• 6877-26-5 C₂₀H₂₃NO₄ 
• 1429118-40-0 2-(4-(benzyloxy)-2-(hydroxymethyl)-3-methoxyphenyl)-N-(3,4-dimethoxyphenethyl)acetamide 
• 1429118-42-2 C₂₆H₂₇NO₆ 
• 1429118-46-6 C₃₃H₃₅NO₆ 

Relevant academic research and scientific papers

Preparation method of isoquinoline alkaloid L-corydalmine

The invention belongs to the field of medical chemistry, and provides a preparation method of L-corydalmine or pharmaceutically acceptable salts thereof. The method comprises the following steps of: in the presence of an organic solvent, catalyzing by pal

Asymmetric total synthesis of tetrahydroprotoberberine derivatives and evaluation of their binding affinities at dopamine receptors

Cocaine addiction remains a serious challenge for clinical and medical research because there is no effective pharmacological treatment. L-THP, a natural product isolated from Corydalis yanhusuo W.T. Wang, is one of the most frequently used traditional herbs to treat drug addiction in China. Our laboratory first reported that its demethylated metabolites L-ICP, L-CD, and L-CP had high affinity at dopamine D1, D2, and D5 receptors. Here we report the chemical synthesis of these metabolites and other derivatives and their binding affinities at dopamine receptors. The synthesis of these bioactive metabolites will allow further in vivo study of their potential in treating cocaine addiction.

DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.

DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF

The present invention relates to a diarylo[a,g]quinolizidine compound of formula (I), enantiomer, diastereoisomer, racemate, mixture, pharmaceutically acceptable salt, crystalline hydrate or solvate thereof; the preparation method thereof, and uses thereof in preparing an experimental model drugs related to dopamine receptors and 5-HT receptors or a medicament for treating or preventing a disease related to dopamine receptors and 5-HT receptors.

HEXAHYDRODIBENZO[A,G]QUINOLIZINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF

The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The pr

Enantioselective total synthesis of (-)-(S)-stepholidine

(Chemical Equation Presented) Enantioselective total synthesis of (-)-(S)-stepholidine, a drug candidate for the treatment of schizophrenia and/or drug abuse, is described. Asymmetric transfer hydrogenation of imines with use of Noyori's catalyst was used